Prevention and Treatment of KSHV-associated Diseases with Antiviral Drugs

作     者：Ren-rong TIAN Qing-jiao LIAO Xulin CHEN 

作者机构：State Key Laboratory of Virology Wuhan Institute of Virology Chinese Academy of Sciences Wuhan 430071China 

出 版 物：《Virologica Sinica》 (中国病毒学（英文版）)

年 卷 期：2008年第23卷第6期

页      面：486-495页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 10[医学] 

基　　金：National Natural Science Foundation of China (30670093) 

主　　题：Antiviral drugs Kaposi's sarcoma-associated herpesvirus (KS HV) Kaposi's sarcoma (KS) Primaryeffusion lymphoma Multicentric castleman disease 

摘      要：Kaposi’s sarcoma-associated herpesvirus (KSHV) was first identified as the etiologic agent of Kaposi’s sarcoma (KS) in 1994. KSHV infection is necessary,but not sufficient for the development of Kaposi sarcoma (KS),primary effusion lymphoma (PEL),and multicentric Castleman disease (MCD). Advances in the prevention and treatment of KSHV-associated Diseases have been achieved,even though current treatment options are ineffective,or toxic to many affected persons. The identification of new targets for potential future therapies and the randomized trial to evaluate the efficacy of new antivirals are required.